7:50 am Chair’s Opening Remarks

• David Alleva Executive Director, Akston Biosciences

An Overview of Progress Towards Achieving Successful Antigen Specific Therapeutics

8:00 am Antigen-Specific Immunotherapy Approaches for the Treatment of Autoimmune Diseases

• Emilio Flano Director & Head of Immunology Discovery, Merck & Co

8:30 am Translating Innovative Science to Therapies that Establish Immune Tolerance – One Pharma’s Perspective

• Arpita Maiti Executive Director & Global Head, Global Head Pfizer

Clinical Readouts & Translation: What can we Learn from the Clinic? Implications for Designing Clinical Trials

9:00 am Antigen-Specific Immunotherapy for Treatment of Autoimmune Diseases

• David Wraith Director of the Institute of Immunology & Immunotherapy , University of Birmingham

9:30 am From Bench to Bedside: Pre-Clinical & Clinical Results of Tolerogenic Therapy of Celiac Disease using Gliadin-Encapsulating PLG Nanoparticles

• Stephen Miller Co-Founder of Cour Pharmaceuticals; Professor of Microbiology- Immunology, Northwestern University Medical School

10:00 am Speed Networking

10:30 am Morning Break & Refreshments

11:00 am From Mechanism to Clinical Trial – Blocking Disease-Specific HLA in Type 1 Diabetes

• Aaron Michels Associate Professor of Pediatrics Medicine, & Immunology, Barbara Davis Center for Diabetes, University of Colorado; Chief Scientific Officer, IM Therapeutics

11:30 am Mitigation of Anti-Drug Antibodies with ImmTOR Tolerogenic Nanoparticles

• Kei Kishimoto Chief Scientific Officer, Selecta Biosciences

12:00 pm Lunch & Networking

Optimizing the Identification of Novel Targets: Evaluation of Antigen & Epitope Discovery

1:00 pm Antigen Discovery for Tolerance Induction (Using Immunoinformatics)

• Anne De Groot Founder, Chief Executive Officer & Chief Scientific Officer, Epivax

1:30 pm Antigen Discovery as Key Prerequisite for Successful Tolerization & Vaccination Strategies in Autoimmune Diseases, Allergies & Oncology

• Roland Martin Head - Department of Neuroimmunology & Multiple Sclerosis Research, University Hospital Zurich

Tolerance Delivery Systems & Trial Design Optimization

2:00 pm The Importance of Tolerance Delivery Systems in Antigen-Specific Immune Tolerance

• Shahrokh Shabahang Chief Innovation Officer, AdiTxt Therapeutics

2:30 pm Afternoon Break & Refreshments

3:00 pm A Review of Clinically Tested ASIT Delivery Systems & Implications for Future Design

• Cory Berkland Cory Berkland Distinguished Professor, School of Pharmacy Pharmaceutical Chemistry, University of Kansas

3:30 pm Bench-to-bedside: Imotope™-based antigen-specific immunotherapy for autoimmune diseases

• Anton Van Oosterhout Scientific Advisor, Imcyse

4:00 pm Panel Discussion title: Optimizing Your Clinical Trial Design: A Case Study From Topas Therapeutics

• Timm Jessen Co-Founder & CEO , Topas Therapeutics

4:30 pm Novel Approaches to Antigen Delivery & Immune Response Monitoring

• Colin Dayan Professor of Clinical Diabetes & Metabolism, Cardiff University School of Medicine

5:00 pm Translational & Clinical Development of Novel, Liver Targeted Immune Tolerance Therapies for Celiac Disease & Multiple Sclerosis

• Stephan Kontos Founder & Chief Scientific Officer, Anokion

5:30 pm Chair’s Closing Remarks

5:40 pm Scientific Poster Session